自体免疫疾病相关共同研究及授权契约:2016～2025年

本报告全面深入分析了全球领先的生物製药公司签署的自身免疫性疾病合作与许可协议，并提供前所未有的资讯取得管道。

本报告详细介绍了2016年至2025年间达成的943项自体免疫疾病协议。

• 目标自体免疫疾病：多发性硬化症、不宁腿症候群、皮肤炎、湿疹、掉髮、干癣、乳糜泻、发炎性肠道疾病、克隆氏症、溃疡性结肠炎、肾丝球肾炎、子宫内膜异位症、免疫性血小板减少性紫斑症、嗜中性白血球减少症、移植物抗毛疾病、手术性疾病、手术性糖尿病系统僵直性脊椎炎、幼年特发性关节炎、干癣性关节炎、类风湿性关节炎、葡萄膜炎、发作性睡病、慢性阻塞性肺病、特发性肺纤维化、结节病、梅尼尔氏症和其他自体免疫疾病。

主要的优点

• 2016 年以来的合约趋势
• 自体免疫领域的合作与授权协议
• 透过基准分析确定市场价值
• 财务条款（预付款、里程碑付款、特许权使用费）
• 按公司、治疗领域和技术类型分类的合约目录
• 主要合约金额
• 最活跃的交易撮合者
• 查看每份合约的资产描述和条款
• 存取合约文件 - 深入了解合约结构
• 尽职调查 - 评估拟议合约条款是否适合您的合作伙伴
• 节省数百小时的研究时间

合约分析可协助您对以下内容进行尽职调查：

• 具体授予或选择哪些权利？
• 合约实际授予合作伙伴哪些权利？
• 授予了哪些独家经营权？
• 合约的付款结构是什么？
• 收入和付款如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 智慧财产权（IPR）将如何处理，所有权归谁？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和结果揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果公司所有权发生变更，合约会如何处理？
• 关于转授权和分包，双方约定了哪些条款？
• 公司通常会包含哪些 "范本条款" ？
• 依合约当事人及合约类型而有所不同的 "范本条款" 有哪些？
• 根据合约法，公司要求适用哪一方（法院）的管辖法律？

目录

摘要整理

第1章 简介

第2章 自体免疫疾病的契约动向

• 各年度的自体免疫相关合约趋势
• 各类型契约分析
• 各产业部门分析
• 各开发阶段分析
• 各技术类型分析

第3章 自体免疫疾病领域的财务条件分析

• 明确指示的财务条件
• 契约总额
• 预付款金
• 里程金
• 权利金费率

第4章 自体免疫疾病的主要交易商与契约

• 最活跃的契约企业
• 最活跃的交易商清单
• 契约金额前几名的契约

第5章 自体免疫疾病:契约文件的名录

• 可取得的联盟契约文件

第6章 自体免疫疾病的契约:治疗标的

• 依治疗标靶划分的自体免疫疾病合约
• 合约目录
• 合约目录：依公司划分
• 合约目录：依技术类型划分
• 交易类型定义
• 关于 Biopharma Research Ltd
• 当前合作
• 当前协议
• 近期目前合作报告标题

Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 943 autoimmune deals from 2016 to 2025.

The report includes coverage of the following autoimmune diseases:

• Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
• The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in autoimmune dealmaking.
• Chapter 3 covers the financial deal terms for deals signed in the autoimmune field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
• Chapter 4 provides a review of the top 25 most active biopharma companies in autoimmune dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive and detailed review of autoimmune deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive directory of autoimmune deals listed by theraeutic target.
• The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since 2016.
• In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse autoimmune collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Autoimmune Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of autoimmune trends and structure of deals entered into by leading biopharma companies worldwide.

Autoimmune Collaboration and Licensing Deals includes:

• Trends in autoimmune dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of autoimmune deal records covering pharmaceutical and biotechnology
• The leading autoimmune deals by value
• Most active autoimmune licensing dealmakers

In Autoimmune Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Autoimmune Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in autoimmune dealmaking

• 2.1. Introduction
• 2.2. Autoimmune deals over the years
• 2.3. Autoimmune deals by deal type
• 2.4. Autoimmune deals by industry sector
• 2.5. Autoimmune deals by stage of development
• 2.6. Autoimmune deals by technology type

Chapter 3 - Financial deal terms for autoimmune deals

• 3.1. Introduction
• 3.2. Disclosed financials terms for autoimmune deals
• 3.3. Autoimmune deal headline values
• 3.4. Autoimmune deal upfront payments
• 3.5. Autoimmune deal milestone payments
• 3.6. Autoimmune deal royalty rates

Chapter 4 - Leading autoimmune dealmakers and deals

• 4.1. Introduction
• 4.2. Most active in autoimmune dealmaking
• 4.3. List of most active dealmakers in autoimmune
• 4.4. Top autoimmune deals by value

Chapter 5 - Autoimmune deal contract document directory

• 5.1. Introduction
• 5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by autoimmune therapeutic target
• Deal Directory
• Deal Directory - Autoimmune deals by company A-Z 2016 to 2025
• Deal Directory - Autoimmune deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Autoimmune deals since 2016
• Figure 2: Autoimmune deals by deal type since 2016
• Figure 3: Autoimmune deals by industry sector since 2016
• Figure 4: Autoimmune deals by stage of development since 2016
• Figure 5: Autoimmune deals by technology type since 2016
• Figure 6: Autoimmune deals with a headline value
• Figure 7: Autoimmune deals with upfront payment values
• Figure 8: Autoimmune deals with milestone payment
• Figure 9: Autoimmune deals with royalty rates
• Figure 10: Active autoimmune dealmaking activity since 2016
• Figure 11: Top autoimmune deals by value since 2016